Olga Taraschenko1, Howard S Fox2, Sean J Pittock3, Anastasia Zekeridou3, Maftuna Gafurova4, Ember Eldridge1, Jinxu Liu5, Shashank M Dravid5, Raymond Dingledine6. 1. Division of Epilepsy, Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska. 2. Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska. 3. Laboratory Medicine and Pathology, Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota. 4. College of Arts and Sciences, University of Nebraska Omaha, Omaha, Nebraska. 5. Department of Pharmacology, Creighton University, Omaha, Nebraska. 6. Department of Pharmacology, Emory University School of Medicine, Atlanta, Georgia.
Abstract
OBJECTIVE: Seizures develop in 80% of patients with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis, and these represent a major cause of morbidity and mortality. Anti-NMDAR antibodies have been linked to memory loss in encephalitis; however, their role in seizures has not been established. We determined whether anti-NMDAR antibodies from autoimmune encephalitis patients are pathogenic for seizures. METHODS: We performed continuous intracerebroventricular infusion of cerebrospinal fluid (CSF) or purified immunoglobulin (IgG) from the CSF of patients with anti-NMDAR encephalitis or polyclonal rabbit anti-NMDAR IgG, in male C57BL/6 mice. Seizure status during a 2-week treatment was assessed with video-electroencephalography. We assessed memory, anxiety-related behavior, and motor function at the end of treatment and assessed the extent of neuronal damage and gliosis in the CA1 region of hippocampus. We also performed whole-cell patch recordings from the CA1 pyramidal neurons in hippocampal slices of mice with seizures. RESULTS: Prolonged exposure to rabbit anti-NMDAR IgG, patient CSF, or human IgG purified from the CSF of patients with encephalitis induced seizures in 33 of 36 mice. The median number of seizures recorded in 2 weeks was 13, 39, and 35 per mouse in these groups, respectively. We observed only 18 brief nonconvulsive seizures in 11 of 29 control mice (median seizure count of 0) infused with vehicle (n = 4), normal CSF obtained from patients with noninflammatory central nervous system (CNS) conditions (n = 12), polyclonal rabbit IgG (n = 7), albumin (n = 3), and normal human IgG (n = 3). We did not observe memory deficits, anxiety-related behavior, or motor impairment measured at 2 weeks in animals treated with CSF from affected patients or rabbit IgG. Furthermore, there was no evidence of hippocampal cell loss or astrocyte proliferation in the same mice. SIGNIFICANCE: Our findings indicate that autoantibodies can induce seizures in anti-NMDAR encephalitis and offer a model for testing novel therapies for refractory autoimmune seizures. Wiley Periodicals, Inc.
OBJECTIVE:Seizures develop in 80% of patients with anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis, and these represent a major cause of morbidity and mortality. Anti-NMDAR antibodies have been linked to memory loss in encephalitis; however, their role in seizures has not been established. We determined whether anti-NMDAR antibodies from autoimmune encephalitispatients are pathogenic for seizures. METHODS: We performed continuous intracerebroventricular infusion of cerebrospinal fluid (CSF) or purified immunoglobulin (IgG) from the CSF of patients with anti-NMDARencephalitis or polyclonal rabbit anti-NMDAR IgG, in male C57BL/6 mice. Seizure status during a 2-week treatment was assessed with video-electroencephalography. We assessed memory, anxiety-related behavior, and motor function at the end of treatment and assessed the extent of neuronal damage and gliosis in the CA1 region of hippocampus. We also performed whole-cell patch recordings from the CA1 pyramidal neurons in hippocampal slices of mice with seizures. RESULTS: Prolonged exposure to rabbit anti-NMDAR IgG, patient CSF, or human IgG purified from the CSF of patients with encephalitis induced seizures in 33 of 36 mice. The median number of seizures recorded in 2 weeks was 13, 39, and 35 per mouse in these groups, respectively. We observed only 18 brief nonconvulsive seizures in 11 of 29 control mice (median seizure count of 0) infused with vehicle (n = 4), normal CSF obtained from patients with noninflammatory central nervous system (CNS) conditions (n = 12), polyclonal rabbit IgG (n = 7), albumin (n = 3), and normal human IgG (n = 3). We did not observe memory deficits, anxiety-related behavior, or motor impairment measured at 2 weeks in animals treated with CSF from affected patients or rabbit IgG. Furthermore, there was no evidence of hippocampal cell loss or astrocyte proliferation in the same mice. SIGNIFICANCE: Our findings indicate that autoantibodies can induce seizures in anti-NMDARencephalitis and offer a model for testing novel therapies for refractory autoimmune seizures. Wiley Periodicals, Inc.
Authors: Andrew M White; Philip A Williams; Damien J Ferraro; Suzanne Clark; Shilpa D Kadam; F Edward Dudek; Kevin J Staley Journal: J Neurosci Methods Date: 2005-12-05 Impact factor: 2.390
Authors: Josep Dalmau; Erdem Tüzün; Hai-yan Wu; Jaime Masjuan; Jeffrey E Rossi; Alfredo Voloschin; Joachim M Baehring; Haruo Shimazaki; Reiji Koide; Dale King; Warren Mason; Lauren H Sansing; Marc A Dichter; Myrna R Rosenfeld; David R Lynch Journal: Ann Neurol Date: 2007-01 Impact factor: 10.422
Authors: Josep Dalmau; Amy J Gleichman; Ethan G Hughes; Jeffrey E Rossi; Xiaoyu Peng; Meizan Lai; Scott K Dessain; Myrna R Rosenfeld; Rita Balice-Gordon; David R Lynch Journal: Lancet Neurol Date: 2008-10-11 Impact factor: 44.182
Authors: Sukhvir K Wright; Richard E Rosch; Max A Wilson; Manoj A Upadhya; Divya R Dhangar; Charlie Clarke-Bland; Tamara T Wahid; Sumanta Barman; Norbert Goebels; Jakob Kreye; Harald Prüss; Leslie Jacobson; Danielle S Bassett; Angela Vincent; Stuart D Greenhill; Gavin L Woodhall Journal: Commun Biol Date: 2021-09-20
Authors: Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis Journal: Pharmacol Rev Date: 2021-10 Impact factor: 18.923
Authors: Michele Simonato; Denes V Agoston; Amy Brooks-Kayal; Chris Dulla; Brandy Fureman; David C Henshall; Asla Pitkänen; William H Theodore; Roy E Twyman; Firas H Kobeissy; Kevin K Wang; Vicky Whittemore; Karen S Wilcox Journal: Nat Rev Neurol Date: 2021-02-16 Impact factor: 42.937
Authors: Ana Paula Bornes da Silva; Rodrigo Braccini Madeira Silva; Leise Daniele Sckenal Goi; Rachel Dias Molina; Denise Cantarelli Machado; Douglas Kazutoshi Sato Journal: Front Neurol Date: 2020-05-12 Impact factor: 4.003
Authors: Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri Journal: Epilepsy Curr Date: 2020-01-22 Impact factor: 7.500
Authors: Bernard S Chang; Vaishnav Krishnan; Chris G Dulla; Nathalie Jette; Eric D Marsh; Penny A Dacks; Vicky Whittemore; Annapurna Poduri Journal: Epilepsy Curr Date: 2020-01-22 Impact factor: 7.500